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Abstract Purpose: To evaluate
the efﬁcacy and safety of intravenous
sildenaﬁl for immediate postoperative
pulmonary hypertension (PH) in
pediatric patients undergoing con-
genital heart surgery. Methods: A
double-blind, multicenter, placebo-
controlled, dose-ranging, parallel-
group trial was conducted. Patients
were randomized to one of three
doses of intravenous sildenaﬁl, or
placebo, for a minimum of 24 h.
Results: The study was heavily
underpowered. Whereas enrollment
of 228 patients (57 per treatment arm)
was required to achieve the sample
size estimate to detect difference
between arms, the sponsor terminated
the study after 15 months owing to
slow patient accrual. Seventeen
patients (median age 5 months)
experiencing postoperative PH were
randomized and treated, ﬁve with
placebo and four each with low-,
medium-, and high-dose sildenaﬁl. In
the ﬁrst 24 h, 40% of placebo and
17% of sildenaﬁl patients required
additional therapy (p = 0.330).
Median time to extubation (3 versus
8 days, p = 0.023) and intensive care
unit stay (6 versus 15 days,
p = 0.008) were shorter for sildenaﬁl
patients. Mean ± standard deviation
systolic pulmonary artery pressure
was reduced with sildenaﬁl (46 ± 11
to 35 ± 6 mmHg, p = 0.027 versus
placebo). No adverse events or sys-
temic hypotension were attributed to
sildenaﬁl. Conclusion: Intravenous
sildenaﬁl reduced pulmonary artery
pressure and shortened time to extu-
bation and intensive care unit stay in
children with postoperative PH.
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Introduction
Childrenwithmanyformsofcongenitalheartdisease(CHD)
are prone to develop postoperative elevation in pulmonary
vascular resistance (PVR) [1]. Resultant pulmonary hyper-
tension (PH) may complicate the postoperative course [2].
PH may develop after cardiopulmonary bypass due to injury
or transient dysfunction of the pulmonary endothelium [3].
Several therapies are currently used for postoperative PH
[sedation, alkalosis, inhaled nitric oxide (iNO), intravenous
prostacyclins, adenosine, and others] [4]. However, intrave-
nous prostacyclins [5] may cause systemic hypotension, and
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ture, the drug is costly, deliverable only as a gas, and may be
associated with rebound PH during withdrawal [6]. A fast-
acting,pulmonary-selective,easilyadministeredagentthatis
safe and without a rebound effect is needed.
Sildenaﬁl acts by inhibiting phosphodiesterase type 5
(PDE5), an enzyme that hydrolyzes intracellular cyclic
guanosine monophosphate (cGMP) to 50-GMP [7] and is
highly expressed in the lungs [8]. Oral sildenaﬁl received
approval for treatment of PH after a double-blind, pla-
cebo-controlled trial showed it to be an effective
treatment of chronic PH in adults [9]. In pediatric patients
undergoing heart surgery, oral sildenaﬁl attenuated
rebound PH after iNO withdrawal during the early post-
operative period [10, 11]. However, when administered
enterally, the bioavailability of sildenaﬁl is only about
40% in healthy subjects [12]. Critically ill children in the
postoperative setting may have unpredictable enteral
absorption [13], such that intravenous sildenaﬁl may be
more appropriate. Although preliminary studies in chil-
dren with intravenous sildenaﬁl report lower pulmonary
arterial pressure (PAP) and PVR after cardiac surgery or
during cardiac catheterization [14, 15], the optimal dose
and the potential adverse effects remain undetermined,
and little information is available on the effect of silde-
naﬁl on mortality and morbidity.
A clinical trial was designed to assess the efﬁcacy,
safety, and resource utilization of intravenous sildenaﬁl in
PH that developed during the postoperative period in
children undergoing corrective congenital heart surgery.
Although the trial was stopped due to slow accrual of
patients, 17 patients were randomized and treated. The
results from these patients are reported herein.
Materials and methods
Study design
From October 2003 to January 2005, a randomized,
multicenter, double-blind, placebo-controlled, dose-rang-
ing, parallel-group study was conducted in children
undergoing corrective cardiac surgery who developed
postoperative PH. Patients were randomized to one of
three doses of intravenous sildenaﬁl, or placebo, for a
minimum of 24 h.
The study was conducted in compliance with the
Declaration of Helsinki and the International Conference
on Harmonisation Good Clinical Practices guidelines.
The study protocol was reviewed and approved by the
local institutional ethics committees. Patients believed to
be at high risk for developing postoperative PH were
identiﬁed before surgery. Written informed consent was
obtained prior to initiation of protocol-speciﬁed proce-
dures from each patient’s parent or legal guardian, and
patient consent was obtained (when applicable) within the
2 weeks before surgery.
Eligibility
All infants or children aged 0 (C34 weeks gestational
age) to 17 years undergoing corrective cardiac surgery
with a clinical diagnosis of postoperative PH within 48 h
of the end of surgery and systolic PAP[50% of systolic
arterial blood pressure ([75% for neonates B28 days)
were eligible (Fig. 1). PH was conﬁrmed by Doppler
echocardiogram using the modiﬁed Bernoulli equation to
the peak velocity of tricuspid regurgitation [p = 4v
2,
where p = peak pressure drop from the right ventricle to
the right atrium and v = peak velocity of tricuspid
regurgitation (m/s)] that has been correlated with invasive
transcatheter measurements [8], or pulmonary artery (PA)
catheter at baseline. The exclusion criteria included: use
of postoperative treatment solely for the purpose of
treating or preventing PH, including agents used at rela-
tively high doses for the purpose of deep/heavy sedation,
such as fentanyl; agents used for continued paralysis, such
as pancuronium (except when used to manage clinical
situations such as open chest or critical airway); alkalin-
ization by methods such as hyperventilation (pCO2
\30 mmHg) or bicarbonate (HCO3) infusion; vasodila-
tors; meeting the criteria for extracorporeal membrane
oxygenation (ECMO); receipt of concomitant nitrates or
NO donors, open-label sildenaﬁl within 48 h prior to
surgery or any time postoperatively; supplemental argi-
nine, long-acting a-blockers, endothelin antagonists (e.g.,
bosentan), or potent cytochrome P450 3A4 inhibitors such
as ritonavir or nicorandil. Additional exclusion criteria
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Fig. 1 Study proﬁle. PAP pulmonary arterial pressure, SBP
systolic blood pressure. *One patient withdrawn before treatment
503were: occurrence of postoperative complications that
resulted in hypoxemia (other than PH) due to lung disease;
serious postoperative bleeding resulting in hypotension;
impaired renal function [serum creatinine[2.5 times the
upper limit of normal (ULN)] or hepatic function (alanine
transaminase or aspartate transaminase [3.0 ULN; con-
jugated bilirubin [2.0 ULN; total bilirubin [2.0 ULN);
and leukopenia (WBC\2,500/ll). Permitted medications
included inotropes, milrinone, and other medication used
to treat congestive heart failure.
Randomization
The patients, parents, all clinical staff, and the investi-
gators were blinded to study drug allocation. An
automated interactive voice response system was used to
assign patients to treatment. Randomization was stratiﬁed
by age (neonate or non-neonate) and by study center to
ensure a balance across treatment groups. The minimi-
zation approach with biased coin assignment was used for
stratiﬁcation. The sponsor (Pﬁzer Inc.) provided 50-ml
vials containing sildenaﬁl 1.0 mg/ml. Placebo was pro-
vided as bags of 5% dextrose in water. The research
pharmacist or other qualiﬁed individual received the
randomized treatment assignment and prepared the bolus
dose and maintenance infusion. The dilution was calcu-
lated according to the patient’s weight such that the
assigned concentration (low, medium, or high) was
infused at the same rate for all patients of a particular
weight so that the staff remained blinded to the study
dose.
Protocol
Baseline echocardiograms were performed to verify the
presence of PH. Baseline hemodynamic parameters (in
patients with a pulmonary artery, left atrial, and/or right
atrial/central venous catheter), inotrope score [16], and
vital signs were measured, and blood samples were col-
lected for serum lactate measurement. Final study
assessments were performed at discharge or 7 days after
study drug infusion, whichever occurred ﬁrst. There was
a follow-up telephone call 28 days after study drug
infusion.
Three intravenous sildenaﬁl dosage regimens were
selected to achieve target sildenaﬁl plasma concentrations
of approximately 40, 120, and 360 ng/ml in the low-,
medium-, and high-dose groups, respectively. Selection of
sildenaﬁl doses for neonates and infants\60 days of age
was to be based on pharmacokinetic data in neonates
obtained from a clinical trial that was ongoing at the time
[17, 18]. Each intravenous sildenaﬁl dose regimen con-
sisted of a bolus loading dose infused over 5 min followed
immediately by a maintenance infusion over 24–72 h
(Supplementary Table 2). After 30 min of study drug
infusion, additional therapy for PH was to be initiated if
clinically indicated based on protocol-deﬁned rules (see
Supplementary Material). If the patient was judged clini-
cally stable at 24 h or longer after randomization, the
infusion was discontinued. The infusion of study drug
continued for a minimum of 24 and maximum of 72 h.
Pharmacokinetics
Plasma sample extracts were analyzed using liquid
chromatography and tandem mass spectrometry for sep-
aration and detection of the analytes. The overall method
imprecision values for the analysis of plasma quality
control samples at concentrations of 3, 30, and 350 ng/ml
were 6.2%, 4.5%, and 6.1%, respectively, for sildenaﬁl.
Statistics
Data are expressed as mean ± standard deviation (SD) if
normally distributed or as median (range). Comparisons
between groups were made with independent t tests and
Wilcoxon tests for continuous variables, exact log-rank
tests for times to event, and chi-square tests for frequen-
cies. A p value\0.05 was considered signiﬁcant.
Assuming that 75% of the placebo patients and 40% of
patients at the highest sildenaﬁl dose would require
additional therapy within 24 h of the start of infusion, a
sample size of 228 patients (57 per treatment arm) was
required to detect this difference with 90% power with a
one-sided type I error rate of 0.025 (corresponding to a
two-sided level of 0.05), using a Hochberg adjustment for
multiple comparisons that results in the minimum one-
sided per-comparison error rate of 0.0085. Allowing for a
postrandomization withdrawal rate of 10%, 252 patients
were required to be randomized.
Endpoints
The primary endpoint was the receipt of any additional
therapy for treatment of postoperative PH within 24 h of
start of study drug infusion. The secondary endpoints
were duration of mechanical ventilation and length of
postoperative hospital stay. Tertiary endpoints included
total duration of administration of additional therapy for
PH, change from baseline in postoperative inotrope scores
at postbaseline assessment times, length of stay in an
intensive care unit (ICU), and deaths within 28 days of
follow-up or during hospital stay. Also, change from
baseline in serum lactate levels and change from baseline
504in hemodynamic parameters (PAP, left atrial, right atrial/
central venous pressure) were determined.
Results
Twenty-seven centers worldwide participated in the
study, but only six centers in France and the USA ran-
domized patients. The sponsor terminated the study after
15 months owing to slow patient accrual. Of 87 patients
screened who provided informed consent, 18 (21%) had
postoperative PH and were randomized. No neonates and
infants less than 60 days old were enrolled because sil-
denaﬁl dosing for these patients remained undetermined.
One patient was withdrawn before treatment. The sub-
sequent analysis was performed on the remaining 17
treated patients (Fig. 1).
Patient characteristics
The median age and weight were 5 months (range
3 months–14 years), and 5.2 kg (range 3.9–60 kg),
respectively. There were eight females (Table 1). Seven
had Down syndrome. Five patients received placebo, and
four patients each received low-, medium-, and high-dose
intravenous sildenaﬁl (Fig. 1). The types of lesions are
presented in Table 1.
Efﬁcacy of sildenaﬁl
Additional therapy after 30 min of protocol infusion and
within the ﬁrst 24 h was required by 2 of 5 (40%) pla-
cebo-treated and 2 of 12 (17%) sildenaﬁl-treated patients
(all doses combined, p = 0.330). No patient from the
intravenous sildenaﬁl high-dose group received additional
therapy within 24 h of start of study drug. Nitric oxide
was the most frequently received additional therapy.
Median time to extubation was shorter for patients on
sildenaﬁl compared with placebo: 3 days (range
1–11 days) versus 8 days (range 4–11 days, p = 0.023;
log rank) (Fig. 2a). Median time to ﬁrst discharge from
the hospital was 12 days in the sildenaﬁl group and
21 days in the placebo group (p = 0.135) (Fig. 2b).
Median time to ﬁrst discharge from the ICU was shorter
for sildenaﬁl patients: 6 days (range 1–12 days) versus
15 days (range 5–15 days, p = 0.008) (Fig. 2c).
During the ﬁrst 4 h of treatment, reduction in systolic
PAP and mean PAP (mean ± SD) was greater with sil-
denaﬁl than placebo: 46 ± 11 to 35 ± 6 mmHg versus
49 ± 12 to 49 ± 17 mmHg (p = 0.027) and 33 ± 10 to
23 ± 5 mmHg versus 37 ± 10 to 36 ± 15 mmHg
(p = 0.055), respectively (Fig. 3, Supplementary Fig. 4).
Reduction in diastolic PAP did not differ by treatment
(21 ± 12 to 13 ± 7 mmHg versus 27 ± 11 to 15 ± 5
mmHg, p = 0.306) (Supplementary Fig. 4). Only minor
reductions in systemic systolic and diastolic blood pres-
sure were observed: 82 ± 14 to 79 ± 13 mmHg versus
72 ± 15 to 73 ± 11 mmHg (p = 0.658) and 49 ± 9t o
45 ± 7 mmHg versus 47 ± 9t o4 3± 14 mmHg (p =
0.813), respectively (Fig. 3, Supplementary Fig. 4).
Other outcome measures
Eight of 17 treated patients, 5 on sildenaﬁl (42%) and 3 on
placebo (60%), received additional therapy up to day 28
of the follow-up. Last postbaseline serum lactate values
ranged from 0.5 to 1.92 mmol/l (median 1.02 mmol/L) in
the three sildenaﬁl groups, and from 1.0 to 2.31 mmol/l
(median 1.2 mmol/l) in the placebo group (p = 0.874).
Similarly, the last postbaseline total inotrope score did not
differ between sildenaﬁl groups (median 10, range 5–32)
and placebo (median 11.5, range 5–24.5; p = 0.909).
Safety
Adverse events were reported in 15 (88.2%) patients;
none were treatment related.
No patients experienced signiﬁcant hemodynamic
compromise while on sildenaﬁl infusion. There were no
differences in mean arterial, left atrial, and central
venous pressure between placebo and sildenaﬁl patients.
No patient experienced a clinically relevant decrease in
oxygenation as measured by pulse oximetry and
reported as an adverse event during infusion of study
drug.
Table 1 Patient characteristics
Characteristic n
Males/females 9/8
Age
[2 months to 2 years 15
[2–12 years 1
[12–17 years 1
Cardiac lesions recorded at screening
Ventricular septal defect only 4
Atrial septal defect, primum type 1
Atrioventricular canal, complete 7
Regurgitant aortic or mitral valve requiring valvuloplasty or
replacement
3
Left heart obstruction with two fully developed ventricles,
including mitral stenosis requiring valvuloplasty or
replacement, supravalvular mitral stenosis, aortic stenosis
1
Truncus arteriosus 1
505Four patients died. Two patients died before random-
ization and the cause of death was related to their
congenital heart disease. Two additional patients from the
placebo group died after randomization. One 6-month-old
female with Down syndrome and ventricular septal defect
experienced respiratory distress 19 days after surgical
closure of the defect. The second postoperative death
occurred in a 14-year-old male who experienced a com-
plicated postoperative course after mitral valve repair
with refractory PH and eventually died from fungal sepsis
on postoperative day 64.
Discussion
In the present study, intravenous sildenaﬁl lowered PAP
and decreased morbidity by shortening the time to extu-
bation and length of ICU stay in a small pediatric
population sample undergoing corrective heart surgery.
Despite the beneﬁt of early correction and improvements
with intra- and postoperative care, postoperative PH still
occurs. In a recent survey, an estimated 2% of pediatric
patients undergoing congenital heart surgery experienced
severe postoperative PH [19]. In our study, we found that,
Fig. 2 Kaplan–Meier analysis
of a time to extubation, b time
to intensive care unit discharge,
and c length of hospital stay for
patients in the placebo group
versus those in the combined
sildenaﬁl group
506in a selected pediatric population considered at risk for
PH, 21% experienced postoperative PH.
Interestingly, a high proportion (7 out of 17) of our
study patients had Down syndrome. It is well known that
patients with Down syndrome exhibit an abnormal pro-
pensity for postoperative PH after congenital heart
surgery. Patients with Down syndrome are readily over-
represented in studies of postoperative PH, accounting for
44–60% of cases [15, 19]. Speciﬁc features associated
with PH in Down syndrome include alveolar hypoplasia
and thickness of small pulmonary arteries [20]. To date,
no speciﬁc study has addressed use of sildenaﬁl in post-
operative PH associated with Down syndrome. However,
management and treatment of such patients with pul-
monary vasodilators do not differ and carry results similar
to those of comparable patients without chromosomal
aberrations [19]. Finally, the true incidence of postoper-
ative PH may be underestimated in this study for the
following reasons: ﬁrst, some patients with life-threaten-
ing postoperative PH were emergently treated with
pulmonary vasodilators or ECMO and could not be ran-
domized to the study; second, neonates and infants aged
\60 days, traditionally accounting for the majority of
postoperative PH cases (particularly following repair of
transposition of the great arteries, truncus arteriosus, and
total anomalous pulmonary venous drainage) [19, 20],
were not included.
Four deaths were reported, two before randomization
and two in the placebo group, suggesting that children
potentially at risk for postoperative PH in the present
study represent an at-risk population for congenital heart
surgery. However, the risk of postoperative PH cannot be
ascertained from this small and selected population
sample. Nevertheless, postoperative PH still carries sig-
niﬁcant morbidity and even mortality. In a recent study,
among 100 patient deaths after congenital heart surgery,
PH was the ﬁfth most frequent etiology, accounting for
8% of the deaths [21]. This is also in agreement with the
results of Lindberg and colleagues, who reported 7.4%
mortality within 30 days postoperatively, and 11% mor-
tality within 1 year in children who underwent cardiac
operations and had severe postoperative PH, despite the
use of speciﬁc therapy, including iNO [19]. This further
emphasizes the need for an optimal strategy to anticipate
and treat postoperative PH.
Our results show that intravenous sildenaﬁl effectively
decreased systolic PAP. However, oral sildenaﬁl is also
often effective [9–11], despite unpredictable bioavail-
ability [12]. Diminished visceral blood ﬂow and
gastrointestinal motility as well as use of opioids can
reduce the absorption of sildenaﬁl, especially after car-
diopulmonary bypass. Whether the intravenous form is
potentially more effective than oral administration
remains undetermined. Similarly, we cannot conclude
from the present study if the intravenous form is associ-
ated with more frequent adverse events.
Unlike previous reports investigating intravenous sil-
denaﬁl after pediatric cardiac surgery [14, 15, 22], this is
theﬁrststudytoexploresildenaﬁlasaninitialtreatmentfor
nonacute postoperative PH. The use of a bolus followed by
amaintenancedoseforamaximumof72 hwasspeciﬁcally
designed to treat postoperative PH. The administration of
intravenous sildenaﬁl at any dose was not associated with
any clinically relevant adverse events. No signiﬁcant sys-
temic vasodilatation occurred compared with placebo. The
results indicate that intravenous sildenaﬁl, administered as
a bolus dose followed by a maintenance dose, seems well
tolerated in this patient population.
The major limitation of this study was the premature
closure of the trial, prompted by slow accrual of patients
with demonstrable PH. Contributing to the slow accrual
was the exclusion of patients who were emergently treated
with a pulmonary vasodilator or ECMO and of neonates
and infants aged\60 days, who were not included. Of the
patients enrolled preoperatively, 21% had signiﬁcant
untreated PH upon reaching the postoperative ICU.
0 1 2 3 4
0
20
40
60
80
100
SBP Placebo
SBP Sildenafil
*p=0.658 and +p=0.027 for change at 4 hours from baseline with sildenafil vs placebo.
SPAP Sildenafil
SPAP Placebo *
+
Time (h)
M
e
a
n
 
S
B
P
 
a
n
d
 
S
P
A
P
,
 
m
m
 
H
g
 
±
 
S
E
M
Fig. 3 Systolic blood pressure
(SBP) and systolic pulmonary
arterial pressure (SPAP) during
ﬁrst 4 h of drug infusion for
patients in the placebo group
versus those in the combined
sildenaﬁl group
507Consequently, 1,086 patients would have needed to be
enrolled to achieve the sample size estimate of 228. Given
the known difﬁculties in executing pediatric trials and the
slow accrual rate (18 patients in 15 months), the original
assumptions made the target enrollment number appear
unattainable. However, in retrospect, the treatment effect
was larger than anticipated, so that a positive trial may
have been seen with far fewer patients. These observations
may have important bearing on planning future studies on
postoperative PH. Nonetheless, with such a limited num-
ber of patients, we could not show convincing efﬁcacy, nor
could we determine the optimal intravenous sildenaﬁl
dose. However, the absence of any clinically relevant
adverse events associated with its efﬁcacy on PAP
(including any important change in continuously moni-
tored pulse oximetry) suggests that use of intravenous
sildenaﬁl is relatively safe at the three doses we used. The
absence of clinically relevant hypoxemia suggests that the
potential adverse impact on intrapulmonary shunt was not
clinically signiﬁcant, although the fact that blood gas
measurements and arterial PO2 were not regularly recor-
ded represents a signiﬁcant study limitation in this regard.
No ﬁrm conclusion can be made about the impact of
intravenous sildenaﬁl on gas exchange. Further studies are
needed to determine the optimal dose needed to decrease
pulmonary vascular resistance while still avoiding signif-
icant adverse events.
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